Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing ctx-m extended-spectrum β-lactamases

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 1278-1280

  Prakash, Vidhya ^a   Lewis II, James S ^b   Herrera, Monica L ^b   Wickes, Brian L ^b   Jorgensen, James H ^b  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFDINIR; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; NITROFURANTOIN; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONCENTRATION RESPONSE; CYSTITIS; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG HALF LIFE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTPATIENT; PRIORITY JOURNAL; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CEPHALOSPORINS; CROSS INFECTION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FOSFOMYCIN; HUMANS; INFUSIONS, PARENTERAL; MICROBIAL SENSITIVITY TESTS; OUTPATIENTS; URINARY TRACT INFECTIONS;

EID: 62949239140     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01519-08     Document Type: Article

References (25)

1. Alhambra, A., J. A. Cuadros, J. Cacho, J. L. Gómez- Garcés, and J. I. Alós. 2004. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J. Antimicrob. Chemother. 53:1090-1094.
2. Bonsu, B. K., L. Shuler, L. Sawicki, P. Dorst, and D. M. Cohen. 2006. Susceptibility of recent bacterial isolates to cefdinir and selected antibiotics among children with urinary tract infections. Acad. Emerg. Med. 13:76-81.
3. Calbo, E., V. Romaní, M. Xercavins, L. Gómez, C. G. Vidal, S. Quintana, J. Vila, and J. Garau. 2006. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamases. J. Antimicrob. Chemother. 57:780-783.
4. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. Clinical and Laboratory Standards Institute. Wayne. PA.
5. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing. Supplement M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Guay, R. P. 2002. Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin. Clin. Ther. 24:473-489.
7. Ho, P. L., W. W. Poon, S. L. Loke, M. S. Leung, K. H. Chow, R. C. Wong, K. S. Yip, E. L. Lai, and K. W. Tsang. 2007. Community emergence of CTX-M type extended-spectrum β-lactamases among urinary Escherichia coli from women. J. Antimicrob. Chemother. 60:140-144.
8. Ho, P. L., R. C. Wong, K. S. Yip, S. L. Loke, M. S. Leung, G. C. Mak, F. K. Chow, K. W. Tsang, and T. L. Que. 2007. Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistant phenotypes. Diagn. Microbiol. Infect. Dis. 59:439-45.
9. Kang, C.-L, H. S. Cheong, D. R. Chung, K. R. Peck, J.-H. Song, M.-D. Oh, and K.-W. Choe. 2008. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Eur. J. Clin. Microbiol. Infect. Dis. 27:85-88.
10. Knottnerus, B. J., S. Nys, G, Ter Riet, G, Donker, S. E, Geerlings, and E. Stobberingh. 2008. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands. J. Antimicrob. Chemother. 62:356-359.
11. Ko, K. S., J. Y. Suh, K. R. Peck, M. Y. Lee, W. S. Oh, K. T. Kwon, D. S. Jung, N. Y. Lee, and J. H. Song. 2007. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum β-lactamase-producing Esche-richia coli isolated from urine and blood. Diagn. Microbiol. Infect. Dis. 58:111-115.
12. Leigh, A. P., M. A. Nemeth, C. H. Keyserling, L. H. Hotary, and K. J. Tack. 2000. Cefdinir versus cefaclor in the treatment of uncomplicated urinaiy tract infection. Clin. Ther. 22:818-825.
13. Lewis, J. S., II, M. Herrera, B. Wickes, J. E. Patterson, and J. H. Jorgensen.2007. First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob. Agents Chemother. 51:4015-4021.
14. Melzer, M., and I. Peterson. 2007. Mortality following bacteraemic infection caused by extended spectrum β-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J. Infect. 55:254-259.
15. Miller, L. A., K. Ratnam, and D. J. Payne. 2001. β-Lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr. Opin. Pharmacol. 1:451-458.
16. Pitout, J. D., D. L. Church, D. B. Gregson, B. L. Chow, M. McCracken, M. R. Mulvey, and K. B. Laupland. 2007. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary health region: emergence of CTX-M-15-producing isolates. Antimicrob. Agents Chemother. 51:1281-1286.
17. CTX-M genes. Clin. Infect. Dis. 38:1736-1741.
18. Pitout, J. D., and K. B. Laupland. 2008. Extended-spectrum βlactamaseproducing Enterobacteriaceae: an emerging public health-concern. Lancet Infect. Dis. 8:159-166.
19. Prakash, V., J. S. Lewis II, M. L. Herrera, B. Wickes, and J. H. Jorgensen.2008. Oral and parenteral therapeutic options for outpatient urinary infections caused by CTX-M ESBL-producing Enterobacteriaceae. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. L-617.
20. Pullukcu, H., M. Tasbakan, O. R. Sipahi, T. Yamazhan, S. Aydemir, and S. Ulusoy. 2007. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinaiy tract infections. Int. J. Antimicrob. Agents 29:62-65.
21. Rodriguez-Baño, J., J. C. Alcalá, J. M. Cisneros, F. Grill, A. Oliver, J. P. Horcajada, T. Tórtola, B. Mirelis, G. Navarro, M. Cuenca, M. Esteve, C. Peña, A, C, Llanos, R. Cantón, and A, Pascual. 2008. Community infections caused bv extended-spectrum β-lactamases-producing Escherichia coli. Arch. Intern. Med. 168:1897-1902.
22. Rodriguez-Baño, J., M. D. Navarro, L. Romero, L. Martínez-Martínez, M, A. Muniain, E. J. Perea, R. Pérez-Cano, and A. Pascual. 2004. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J. Clin. Microbiol. 42:1089-1094.
23. Rodriguez-Baño, J., M. D. Navarro, L. Romero, M. A. Muniain, M. de Cueto, M. J. Rios, J. R. Hernández, and A. Pascual. 2006. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis. 43:1407-1414.
24. Tamayo, J., B. Orden, J. Cacho, J. Cuadros, J. L. Gómez- Garcés, and J. I. Alós. 2007. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid. Rev. Esp. Quimioter. 20:334-338.
25. Woodford, N., M. E. Ward, M. E. Kautmann, J. Turton, E. J. Fagan, D. James, A. P. Johnson, R. Pike, M. Warner, T. Cheasty, A. Pearson, S. Harry, J. B. Leach, A. Loughrey, J. A. Lowes, R. E. Warren, and D. M. Livermore. 2004. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J. Antimicrob. Chemother. 54:735-743.